10 stories
Generic Semaglutide Approval, Retatrutide Phase III, Oral GLP-1 War Heats Up
Apotex wins first generic semaglutide approval, retatrutide aces Phase III, and the Foundayo vs oral Wegovy rivalry intensifies.
Read digest →Peptide News Digest
Latest peptide research, regulatory updates, and industry news. Your daily source for peptide science developments.
Latest Digests
View all → 10 stories
Foundayo Launch, FDA Compounding Crackdown, Merck Oral PCSK9 Inhibitor, Reddit GLP-1 Side Effects Study
Lilly launches Foundayo with $1.5B pre-stocked; FDA escalates compounding crackdown; Merck oral peptide PCSK9 inhibitor impresses; Reddit study reveals GLP-1 side effects.
Read digest → 10 stories
Health Canada Peptide Warning, GLP-1 Genetics Study, India Semaglutide Price War
Health Canada warns against unauthorized peptides; Nature GWAS links GLP1R variants to weight loss; Indian generic semaglutide surges past Mounjaro.
Read digest → 10 stories
FDA Clears GLP-1 Suicide Concerns, Oral Wegovy Explosion, Foundayo Launches at $25/Month, Utah Peptide Indictment
FDA finds no suicide risk with GLP-1s, oral Wegovy draws explosive demand, Lilly's Foundayo launches at $25/month, and a Utah physician is indicted for importing peptides.
Read digest → 10 stories
GLP-1 Pricing Deal, Retatrutide Phase 3, Peptide Safety Investigations
Landmark GLP-1 pricing drops to $245/mo, Lilly's retatrutide aces Phase 3, and investigations expose peptide quality failures and safety risks.
Read digest → 10 stories
Pinnacle Medicines $89M for Oral Peptides, Cagrilintide Phase 3 Monotherapy Results, Higher-Dose Wegovy 21% Weight Loss
Pinnacle raises $89M for oral peptides matching biologics, cagrilintide shows Phase 3 obesity results, and higher-dose Wegovy achieves 21% weight loss.
Read digest → 10 stories
MHRA Peptide Clinic Probe, GLP-1 Price War, Orforglipron Approval
UK MHRA investigates peptide clinics, GoodRx matches oral semaglutide pricing, FDA approves Eli Lilly oral GLP-1, and India tightens GLP-1 oversight.
Read digest → 10 stories
RFK Jr. Peptide Ban Reversal, Retatrutide Phase 3 Results, Oral Semaglutide vs Orforglipron
RFK Jr. moves to reverse FDA peptide ban amid safety pushback; Lilly retatrutide hits Phase 3 endpoints; oral semaglutide may outperform orforglipron.
Read digest → 10 stories
Foundayo FDA Approval, Retatrutide TRIUMPH-4 Results, Semaglutide Safety Signal, Health Tech Peptide Bets
Eli Lilly's oral GLP-1 Foundayo approved in record time; retatrutide hits 28.7% weight loss in Phase 3; semaglutide linked to rare skin condition.
Read digest → 10 stories
FDA Approves Orforglipron, GLP-1 Cardiovascular Benefits, India Regulatory Crackdown
FDA approves Eli Lilly's Foundayo, the first small-molecule GLP-1 pill for obesity. GLP-1 drugs show heart and kidney benefits in Type 1 diabetes.
Read digest → 10 stories
FDA Peptide Ban Reversal, GLP-1 Telehealth Crackdown, Novo Nordisk India Price Cuts
FDA expected to lift peptide compounding ban at RFK Jr.'s urging; 30 telehealth firms warned; Novo slashes Ozempic prices in India; UK expands Wegovy prescribing.
Read digest → 10 stories
Retatrutide Clears Fatty Liver in 85% of Patients, Cagrilintide Phase 3 Obesity Data, GLP-1s for Substance Use Disorders
Retatrutide clears fatty liver in 85%+ of patients, cagrilintide posts Phase 3 obesity results, and Lilly investigates GLP-1s for substance use disorders.
Read digest →